2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2334

Ultrasound-Guided Facet Joint Injections through a Longitudinal Approach
Abstract Number: 1187

Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry
Abstract Number: 2871

Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Abstract Number: 567

Understanding Contextual Factors That Influence Decisions Related to Health and Work Among People with Recently Diagnosed Rheumatoid Arthritis
Abstract Number: 1241

Understanding Lupus Patients’ Ability to Work with Numbers
Abstract Number: 2342

Understanding Patient Barriers and Facilitators to Healthy Eating and Physical Activity before and after Knee Replacement
Abstract Number: 81

Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Abstract Number: 1345

Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time
Abstract Number: 2764

Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample
Abstract Number: 2130

Unloading Results in Rapid Loss of TGFβ Signaling in Cartilage: Role of Loading-Induced TGF-Β Signaling in Maintenance of Articular Chondrocyte Phenotype?
Abstract Number: 258

Unmet Psychosocial Needs in Patients with CAPS
Abstract Number: 788

Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
Abstract Number: 2576

uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis
Abstract Number: 2391

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 80 Patients at First Assessment
Abstract Number: 1685

Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].